STOCKHOLM, Nov. 17, 2020 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced that its Hummingbird family of intracranial pressure
(ICP) monitoring equipment has been awarded a group purchasing
agreement with Premier Inc. in the United
States. Effective December 1, the new agreement allows
Premier members, at their discretion, to take advantage of special
pricing and terms pre-negotiated by Premier for Hummingbird ICP
Monitoring products.
Premier added the Hummingbird products to its list of
contractually approved items in the neurosurgical critical care
product category via its Technology Breakthroughs program. This
selective program allowed IRRAS to gain status as an approved
supplier outside of Premier's normal contract cycle.
"Today's announcement is a significant accomplishment for the
commercial growth of IRRAS," said Will Martin, IRRAS'
President and Chief Commercial Officer. "This contract accelerates
our US Hummingbird launch by allowing our team to introduce the
product to Premier's broad membership group of approximately 4,100
hospitals."
Assessment of a patient's ICP is a critical element of managing
traumatic brain injury, and the Hummingbird product family is
designed to continuously monitor a patient's ICP by placing a small
probe directly into the brain tissue. Instead of using strain gauge
or fiberoptic sensors like other ICP monitors, the Hummingbird
system uses a small air bladder that allows simple setup and
automatic, hourly ICP recalibration. This air bladder mechanism of
action eliminates challenges that plague other systems, including
cumbersome setup and ICP readings that cannot be recalibrated and
become increasingly inaccurate over time.
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,100 US hospitals and 200,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and advisory and
other services, Premier enables better care and outcomes at a lower
cost.
1. Severe TBI. Centers for Disease Control and
Prevention, Centers for Disease Control and Prevention,
2 Apr. 2019,
www.cdc.gov/traumaticbraininjury/severe.html.
2. Traumatic Brain Injury Fact sheets and
Policy brief. Center-TBI,
https://www.center-tbi.eu/files/news/21571f81-20b8-4860-a3dd-1f6e27d02b3d.pdf.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications
associated with current treatment methodologies. IRRAS markets
and sells its comprehensive, innovative IRRAflow and Hummingbird
ICP Monitoring product lines to hospitals worldwide through its
direct sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker:
IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on November 17, 2020 at 08:00 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-awarded-breakthrough-technology-purchasing-agreement-with-premier-for-hummingbird-icp-monitori,c3238184
View original
content:http://www.prnewswire.com/news-releases/irras-awarded-breakthrough-technology-purchasing-agreement-with-premier-for-hummingbird-icp-monitoring-products-301174340.html
SOURCE IRRAS